Skip to main content

Top Menu

  • Contact
  • Media
  • Careers
  • Staff
  • About Us
    • About CCTG
    • CCTG Strategic Plan 2022-2027
    • Committee Leadership
    • CCTG Scientific Leadership
    • CCTG Management
    • Careers at CCTG
    • CCTG policies
    • Contact us
  • Patients & Families
    • Patients & Families
    • Patient Representatives Committee
    • Patients as research partners
    • Resources for patients & families
    • Clinical trials - public
  • Disease Site Listings - Public

    Disease Site Listings - Public

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Multi-Site
    • Sarcoma
    • Symptom Control
  • Disease Site Listings - Members

    Disease Site Listings - Members

    • All
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
  • Clinical Trials
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Clinical trials - overview
    • All Trials
    • Brain
    • Breast
    • Gastro-Intestinal
    • Genito-Urinary
    • Gynecologic
    • Head & Neck
    • Hematologic
    • IND
    • Lung
    • Melanoma
    • Sarcoma
    • Symptom Control
    • Multi-Site
    • Publications

    Mobile CCTG Clinical Trials

    • Member Trial Pages
    • Public Trial Pages
    • Publications
    SPECT-CT Guided ELEctive Contralateral Neck Treatment (Select) for Patients with Lateralized Oropharyngeal Cancer.

    Now open, the HN11 SELECT trial looking at a personalized radiotherapy treatment for throat cancer

    CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)

    More >>

    Recently Activated Trials

    BLC5

    MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer

    More >>

    EN10

    Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)

    More >>

    HN11

    SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)

    More >>

    I241

    A Liquid-biopsy Informed Platform Trial to Evaluate Treatment in CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

    More >>
  • Member Resources

    Member Links

    • Current trials
    • Disease site & IND committees
    • Standing committees
    • Leadership resources
    • Become a member
    • Funding information
    • Compliance & oversight
    • Audit, inspection & partner compliance
    • Generic protocols
    • Group newsletter: CCTG Connection
    • Help & Support
    • Terms of reference
    Expansion of the Tissue Bank facilities

    Expansion of the Tissue Bank facilities

    The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.

    More >>

    Planned Trials

    AL6

    MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML

    ALC7

    Master Screening and Reassessment Protocol (MYELOMATCH) for the NCI myeloMATCH clinical trials

    ALC8

    Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)

    ALC9

    Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)

    CRC10

    Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    EN11

    RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features. The MMRD-GREEN trial

    More >>

    GA4

    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

    HD12

    PET Response Adapted Design Comparing ABVD +/- ISRT with A2VD +/- ISRT in Patients with Stage IA/IIA Hodgkin Lymphoma (RADAR)

    HN12

    PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)

    More >>

    HN13

    Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)

    I242A

    A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC

    ME16

    Adjuvant Treatment Guided by Response Post Neoadjuvant Therapy for Stage III Melanoma

    NE1

    NET RETREAT: 177Lutetium- DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Midgut NET

    More >>

    PR23

    Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy

    PR24

    Androgen Suppression combined with Elective Nodal and a Dose Escalated Boost. Stereotactic Body Radiation Therapy vs Brachytherapy Boost (ASCENDE-SBRT)

    PR25

    Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes

    SC28

    The SEEMLESS Study: A randomized trial of a SmartphonE App-based MindfuLnEss intervention for cancer SurvivorS

    VU2

    STRatIfication of Vulvar squamous cell carcinoma by HPV and p53 status to guide Excision: STRIVE Study

    Disease Site Committees

    • Brain
    • Breast
    • Gastro-Intestinal
    • Gynecologic
    • Genito-Urinary
    • Head & Neck Working Group
    • Hematologic
    • IND
    • IND Executive
    • Lung Disease
    • Melanoma
    • Sarcoma
  • Meetings & Education
    • Spring meeting of participants
      • CCTG recognition awards
      • Maria Ricci Memorial Lecture
    • New investigator cancer trials practicum
    • New investigator clinical trials course
    • Fellowships
    • The Frances A Shepherd Award
    • Conference presentations
  • Search
  • Donate
  • Toolbox
    • Applications
    • >>  EDC (Medidata Rave)
    • >>  iMedidata
    • >>  Mango
    • >>  Ripple
    • >>  Lettuce
    • >>  Sprout (ePRO)
    • Exposure Reporting
    • >>  CTEP website
    • >>  CTCAE v5.0 booklet
    • >>  CTCAE v4.0 booklet
    • >>  CTCAE v3.0 booklet
    • >>  CTEP-AERS reporting
    • >>  EDC SAE (paper report)
    • >>  Pregnancy reporting form
    • >>  Exposure reporting form
    • Support
    • >>  Passwords management
    • >>  CCTG contacts
    • >>  Support information
    • Tissue Bank
    • >>  Tissue Bank
    • >>  Inventory
    • >>  Tissue research
    • Reports
    • >>  Accrual utility (Monthly site accrual)
    • >>  Safety reports
    • >>  Papaya
    • >>  Ethics
    • >>  Trial closure
    • Data Management
    • >>  Baseline symptoms & adverse events
    • >>  Concomitant medications template
    • >>  SI conversion table
    • >>  iRECIST & RECIST guidelines
    • Training
    • >>  NIH ethics training
    • >>  Division 5 part C
    • >>  Good clinical practice
    • >>  Site training
    • >>  Supplementary training
  • Contact Us
  • Media
  • Staff

  For the latest COVID-19 (Coronavirus) information: CCTG public updates | CCTG member information

Staff Links

Email

  • Zimbra
  • Messenger Express (access your email prior to June 2012)

Intranet

  • CCTG Intranet
 

Instructions for Working at Home

  • Working at Home

File Sharing

  • Nextcloud
  • Partnerships 600+ trials in 40+ countries
  • IND Program 38+ years experience in 205+ drug trials
  • Tissue Bank 300,000+ samples from 120+ trials
  • Network 2100+ investigators at 85+ sites
  • Become a CCTG Investigator
CCTG Strategic Plan 2022-2027
CCTG Strategic Plan 2022-2027

Footer Menu

  • About us
  • Patients & Families
  • Clinical trials
  • Member resources
  • Meetings & Education
  • Publications
  • Toolbox
  • Contact us
  • Media centre
  • Staff
  • Careers

CANADIAN CANCER TRIALS GROUP

Cancer Research Institute
Queen's University

10 Stuart Street
Kingston, Ontario
Canada K7L 3N6

A NATIONAL PROGRAM OF THE:

 

OPERATIONS AND STATISTICAL CENTRE LOCATED AT:

PROUDLY AFFILIATED WITH:

As a national cooperative group, CCTG recognizes that Canada is situated on Indigenous lands, we acknowledge that the Operations and Statistics Centre, located at Queen’s University, is located on traditional Anishinaabe and Haudenosaunee Territory.
© Canadian Cancer Trials Group, 2021 | Terms & Conditions Facebook LinkedIn TwitterYouTube